Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc (NASDAQ:RPRX), conducted a sale of corporate shares on May 20, 2026. Mr. Urist disposed of 13,684 Class A Ordinary Shares, generating proceeds valued at $721,837.
The details surrounding the divestiture indicate that the transaction was executed under a prearranged trading plan, specifically a 10b5-1 plan, which had been adopted on February 12, 2026. The shares sold were priced at a weighted average of $52.7505 per share. Furthermore, individual sale prices for these specific shares ranged between $52.62 and $52.96.
Current Holdings and Valuation Context
The timing of this sale is notable given the current market performance of RPRX stock. The company's shares are currently trading close to their 52-week high, which stands at $53.59. This appreciation follows a substantial return of 69% over the preceding year.
Analyst analysis from InvestingPro suggests that, relative to its Fair Value, the stock may currently appear overvalued, with shares trading at a Price-to-Earnings (P/E) ratio of 28. Following the recent sale, Mr. Urist's direct holdings are reported as 18,197 Class A Ordinary Shares. His indirect ownership includes an additional 19,020 Class A Ordinary Shares held through an IRA.
Beyond these publicly tracked shares, Mr. Urist and related family controlled vehicles maintain various interests in the company's structure. These include limited partnership interests in RPI US Partners 2019, LP, which are convertible into 2,474,120 Class A Ordinary Shares. Additionally, he possesses Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH"), which can be exchanged for 1,356,528 Class A Ordinary Shares, although these shares remain subject to vesting conditions.
Recent Financial Performance
In separate operational news, Royalty Pharma Plc recently released its financial results for the first quarter of 2026. The company reported a strong period of performance, characterized by double-digit growth in both portfolio receipts and royalty receipts.
While specific forecasts regarding earnings per share (EPS) or overall revenue were not disclosed, the positive investor sentiment surrounding the report was apparent. Royalty Pharma attributed this robust operational strength to two key elements: a diversified portfolio structure and strategic investments made by the company. These developments collectively underscore the firm's confidence in its capacity for sustained long-term growth momentum. The financial outcomes confirm the company's ability to maintain strong growth trajectory.
The lack of any analyst upgrades or downgrades reported in connection with these recent earnings further contributes to the current market narrative surrounding the company's sustained performance.